NextFerm Technologies Ltd.

Investor Presentation • Apr 16, 2024

NEXTFERM TECHNOLOGIES

Leading The Alternative Protein Revolution

April-2024

DISCLAIMER

This presentation is intended for the provision of non-comprehensive information for the sake of convenience solely. You are hereby referred to the full prospectus and immediate and periodic reports filed by the company with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. for information regarding the Company's activities and the risks entailed thereby, including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, that is included therein. In case of any discrepancy between the information contained herein and the information contained in the official reports of the Company to the Israeli Securities Authority and the Tel Aviv Stock Exchange, the information recorded in such reports shall prevail.

This presentation may include forward-looking statements and forward- looking information, including, but not limited to developments, outlooks, projected economy measures, etc.. Such forward-looking statements and information are based on the current assumptions, intentions and plans of the Company. The forward-looking information in the presentation is subject to risks and uncertainties and may not materialize, in whole or in part, or may materialize significantly differently than as predicted, or may be affected by various factors, including factors that are not under the Company's control or such that cannot be estimated in advance. The Company makes no representation or warranty of any kind with respect to such information.

For the avoidance of doubt, it is clarified that the Company does not undertake to update and/or modify the information included in this presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation.

This presentation does not constitute an offer, invitation or recommendation to purchase, sell, subscribe for or do any transactions in the securities of the Company, in any jurisdiction, and the information provided in this presentation is not a basis for the making of any investment decision, nor a recommendation or opinion, nor a substitute for the discretion and independent analysis of any potential investor.

This presentation includes information from public sources, which was not independently examined by the Company and the Company is not liable as to its accuracy.

ABOUT NEXTFERM LEADING THE ALTERNATIVE PROTEIN REVOLUTION

Experienced team in the world of Nutrition and food-tech

ProteVin™ - The only vegan protein with animal like nutritional value and neutral taste Innovative technology based

Demands for ProteVin™ from the growing alternative protein market

Production has started following scale up and launch based on a profitable process

NEXTFERM The team

4

4

Experienced Team in the Food and Food-tech Industries

Company management is comprised of former Senior Management of Enzymotec, which developed innovative ingredients within the world of nutrition. Enzymotec reached revenues of over \$80M and went public (NASDAQ) during 2013, with a market cap of \$300M

ProteVin was tested and approved as appropriate for wide variety of food and dietary supplement products

"Every Tenth Portion of Meat, Eggs, Dairy, and Seafood Eaten Around the Globe Will Be Made from Alternative Proteins by 2035, "

BY 2035, THE ALTERNATIVE PROTEIN MARKET (B2C) IS EXPECTED TO REACH AT LEAST

\$290B(*)

(*) https://www.bcg.com/press/23march2021-alternative-protein-market-reach-290-billion-by-2035

OVER \$300M(*) YEARLY GROWTH IN DEMAND FOR VEGAN PROTEIN POWDER

https://www.gminsights.com/industry-analysis/vegan-protein-powder-market Growth for 2022 and forecast for 2032 (*)

7

- COMMERCIAL STATUS

Above 100 food and dietary supplement companies are evaluating ProteVin™

• 5 launches

• Many Customers are waiting for ProteVIn™.

Above \$3M in PO's & Supply Agreement

5 LAUNCHES

Currently In the market Innovative Proteins NextFerm innovation

Plant based protein sources:

• Poor nutrition value
• Distinguished Taste

Precise fermentation & cell-culture:

• Far from mature
• Super expensive

Protevin™ Superior Nutrition Neutral taste Cost effective

Other Yeast proteins

• All big players are trying
• Poor taste and texture

BREAKTHROUGH TECHNOLOGY

FOR PRODUCING YEAST-DERIVED, INNOVATIVE, FUNCTIONAL VEGAN FOOD INGREDIENTS

Yeast Improvement (Patented, Non-GMO)

Improvement of yeast characteristics for either elevated expression of specific metabolites, stress resistance, and yield

Fermentation (Cost-effective)

Process optimization for economical production of the improved strain biomass

Separation & Purification

Development of efficient purification process for obtaining the desired ingredients applicable to food or dietary supplement

Scale-up (from Lab to Industry)

Implementation of the fermentation and purification processes to full production scale

VEGAN PROTEINS OPTIONS IN THE MARKET

Protein Source	ProteVin™	Other Yeast Proteins (*)	Soy	Pea & Rice
Vegan Source	+	+	+	+
No Allergens/impurities	+	+	-	-
Sustainability	++	++	+	+
Taste & Flavor	++	-	+	-
Applicability	++	-	+	-
Amino Acid Composition (AA)	++	++	-	-
Digestibility	++	++	+	+

¹³ (*) Produced by leading global yeast companies: Lesaffre, Lallemand & Angel Yeast)

ZERO WASTE PROFITABLE PROCESS

(*) https://www.fortunebusinessinsights.com/yeast-extract-market-106656

Multi billions \$ market

~\$2B market (*)

PRODUCTION – KOTHARI INDIA STRONG STRATEGIC PARTNERSHIP

OUR MISSION - BIG SCALE EXECUTION OF PROVEN CASE STUDY

16

16

PROTEVIN – OPERATIONAL PLAN

First Line Installment & commissioning

The first line was installed and operated, and the commissioning was successfully ended

Capacity growth

By the end of Q2, the company will increase capacity to enable expected capacity supporting \$4M annual sales

Further Capacity growth

During 2025 additional stage of expansion is planned for capacity enabling profitability (*)

(*) Long-term Strategy

17

KEY GOALS FOR 2024

Expansion of the production line for ProteVin™ in India, which will enable annual revenues of approximately \$4 million; expected to be completed during the second quarter of 2024

Keep growing market demands and receipt of additional purchase orders for ProteVin™ from the US, Europe and other territories, including a launch in the food sector with a major food manufacturer.

Entering into a collaboration with a Yeast Extract manufacturer, which will allow the company to expand its product portfolio, increase profitability and sales, and strategically penetrate this market.

Initiating sales of the by-products obtained in the protein production process (Yeast Extract & Cell-walls).

-

Achievements 2022 Achievements 2023

Increase demands

Strain commercial scale-up

Production agreement

Well-being

Sports Nutrition Dairy alternative products

Strategic market expansion plan

Senior Nutrition

Infant Nutrition

Commissioning GFR

Commercial Launch

Creating demands

Growth Project 1

Regulation in Israel

FINANCIAL INFORMATION

Cash & cash equivalent as of December 31st , 2023 : ~\$3.3M

Market The cash will be use for ongoing activity and for establishing production in India

\$36M were raised (2014-2023)

B2C 2021

Public Offering in the TASE (March 2023): Raised \$5M Private Placement (December 2021): Raised \$8M TASE IPO (January 2021): Raised \$11M, Market cap of \$33M Former Equity Rounds (Private investments): Raised \$12M

FINANCIAL INFORMATION

thousands in USD	2023	2022	2021
STATEMENT OF OPERATION
Net Revenues	283	262	242
(Loss) Profit (**) Gross	(696)	(1 122) ,	2 3
Market Operating Loss	(4 360) ,	(8 100) ,	(4 467) ,
B2C 2021 Adjusted (*) EBITDA	(3 670) ,	(7 275) ,	(4 113) ,
BALANCE SHEET
Cash cash equivalents and Short deposits term ,	3 281 ,	3 024 ,	13 164 ,
Working Capital	847	511	10 151 ,
Total Assets	8 742 ,	8 093 ,	16 468 ,
Share Capital	5 003 ,	4 047 ,	11 674 ,
CASH FLOW
Cash used in operating activities	(3 800) ,	(7 633) ,	(3 823) ,
Cash used in investing activities	(716)	(2 159) ,	(1 259) ,
Cash used financing in activities	4 813 ,	(212)	17 504 ,

(*) Net profit excluding Interest, taxes, depreciation, amortization and share based compensation

(**) The gross loss is mainly drived from production in a semi industrial facility with a capacity of tens of tons per year, the fixed expenses are distributed over a limited production volume. The expansion of the production line in India, is expected to be finalized during Q2, 2024

THANK YOU!